Fixed Chemo Combo Vyxeos Approved for High-Risk AML Fixed Chemo Combo Vyxeos Approved for High-Risk AML
The fixed chemotherapy combination of daunorubicin and cytarabine, Vyxeos, has been approved for certain cases of high-risk acute myeloid leukemia.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Health | Hematology | Leukemia